Design approach developed for bitopic kinase inhibitors targeting ABL1 and EGFR
Researchers enable development of bitopic inhibitors with enhanced activity against resistance mutations and reduced off-target toxicity.
This story has stopped developing; this page is its permanent record. More from that day
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- ABL1
- EGFR